NCT04933383View on ClinicalTrials.gov

Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

January 31, 2023

Conditions
Asthma
Interventions
DRUG

AQ001S 0.125 mg/ml

administered by nebulization once daily

DRUG

Budesonide 0.125 mg/ml inhalation suspension

administered by nebulization once daily

Trial Locations (1)

5101

Pneumocare SPRL, Erpent

Sponsors
All Listed Sponsors
lead

Aquilon Pharmaceuticals S.A.

INDUSTRY

NCT04933383 - Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics | Biotech Hunter | Biotech Hunter